cardiovascular safety of celecoxib | nejm
Published 7 years ago • 160K plays • Length 2:47Download video MP4
Download video MP3
Similar videos
-
2:21
antiinflammatory therapy and cardiovascular events
-
2:21
inactivation of angptl3 and cardiovascular disease
-
1:49
polypill in secondary cv prevention | nejm
-
2:02
beta-blocker use after myocardial infarction | nejm
-
3:25
precision exonerates celecoxib: cardiovascular risk is no worse than that of nonselective nsaids
-
2:16
apixaban in subclinical atrial fibrillation | nejm
-
1:07
the courage trial
-
1:48
the sprint trial
-
2:08
the fire and ice trial
-
2:23
empagliflozin after acute myocardial infarction | nejm
-
2:09
cardiovascular outcomes in patients with diabetes
-
5:59
toxidrome recognition and response in chemical-weapons attacks | nejm
-
1:34
the stop-it trial
-
1:25
the recess trial
-
6:54
cantos (2017 nejm) and colcot (2019): anti-inflammatory medications for coronary artery disease
-
1:41
the avica trial
-
4:58
randomized evaluation of celecoxib integrated safety versus ibuprofen or naproxen
-
1:54
early estimation of esrd risk
-
1:47
improving outcomes in stroke